Skip to main content

Research Repository

Advanced Search

The SSTARS (STeroids and Stents Against Re-Stenosis) Trial: Different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention

Adam, Z.; Turley, A.; Mason, J.M.; Kasim, A.S.; Newby, D.; Mills, N.; Padfield, G.; Thompson, L.; Morley, R.; Hall, J.A.; Wright, R.A.; Muir, D.F.; Sutton, A.G.C.; Swanson, N.; Carter, J.; Bilous, R.; Jones, S.; de Belder, M.A.

The SSTARS (STeroids and Stents Against Re-Stenosis) Trial: Different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention Thumbnail


Authors

Z. Adam

A. Turley

J.M. Mason

A.S. Kasim

D. Newby

N. Mills

G. Padfield

L. Thompson

R. Morley

J.A. Hall

R.A. Wright

D.F. Muir

A.G.C. Sutton

N. Swanson

J. Carter

R. Bilous

S. Jones

M.A. de Belder



Abstract

Background Stent design and technological modifications to allow for anti-proliferative drug elution influence restenosis rates following percutaneous coronary intervention (PCI). We aimed to investigate whether peri-procedural administration of corticosteroids or the use of thinner strut cobalt alloy stents would reduce rates of binary angiographic restenosis (BAR) after PCI. Methods This was a two centre, mixed single and double blinded, randomised controlled trial using a factorial design. We compared (a) the use of prednisolone to placebo, starting at least six hours pre-PCI and continued for 28 days post-PCI, and (b) cobalt chromium (CoCr) to stainless steel (SS) alloy stents, in patients admitted for PCI. The primary end-point was BAR at six months. Results 315 patients (359 lesions) were randomly assigned to either placebo (n = 145) or prednisolone (n = 170) and SS (n = 160) or CoCr (n = 160). The majority (58%) presented with an ACS, 11% had diabetes and 287 (91%) completed angiographic follow up. BAR occurred in 26 cases in the placebo group (19.7%) versus 31 cases in the prednisolone group (20.0%) respectively, p = 1.00. For the comparison between SS and CoCr stents, BAR occurred in 32 patients (21.6%) versus 25 patients (18.0%) respectively, p = 0.46. Conclusion Our study showed that treating patients with a moderately high dose of prednisolone for 28 days following PCI with BMS did not reduce the incidence of BAR. In addition, we showed no significant reduction in 6 month restenosis rates with stents composed of CoCr alloy compared to SS (http://www.isrctn.com/ISRCTN05886349).

Citation

Adam, Z., Turley, A., Mason, J., Kasim, A., Newby, D., Mills, N., …de Belder, M. (2016). The SSTARS (STeroids and Stents Against Re-Stenosis) Trial: Different stent alloys and the use of peri-procedural oral corticosteroids to prevent in-segment restenosis after percutaneous coronary intervention. International Journal of Cardiology, 216, 1-8. https://doi.org/10.1016/j.ijcard.2016.04.105

Journal Article Type Article
Acceptance Date Apr 11, 2016
Online Publication Date Apr 29, 2016
Publication Date Aug 1, 2016
Deposit Date May 23, 2017
Publicly Available Date Mar 29, 2024
Journal International Journal of Cardiology
Print ISSN 0167-5273
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 216
Pages 1-8
DOI https://doi.org/10.1016/j.ijcard.2016.04.105
Related Public URLs http://wrap.warwick.ac.uk/79375/

Files





You might also like



Downloadable Citations